Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to misfolded, unstable proteins caused by genetic mutations. This technology represents a novel, next-generation approach to the management of human genetic diseases and offers the potential to improve treatment options for many patients. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. The company believes pharmacological chaperone technology has broad applicability and expects to expand the portfolio to include other diseases of neurodegeneration, metabolic diseases, and oncology. Founded in 2002, Amicus has assembled an outstanding leadership team that includes scientific, medical, regulatory, and business professionals with successful track records of developing and bringing to market drugs for genetic diseases. Amicus continues to develop its pharmacological chaperone technology and has built a significant intellectual property portfolio along with its robust clinical and preclinical pipeline. Amicus has a fast-paced, high-energy, entrepreneurial team environment where employees are encouraged to be innovative and resourceful. Amicus seeks high-caliber, talented individuals with a passion to succeed.
Company Growth (employees)
Type
Public
HQ
Cranbury Township, US
Founded
2002
Size (employees)
263 (est)+43%
Amicus Therapeutics was founded in 2002 and is headquartered in Cranbury Township, US

Key People at Amicus Therapeutics

William D. Chip Baird

William D. Chip Baird

Chief Financial Officer
Bradley L Campbe

Bradley L Campbe

Chief Operating Officer
Jeffrey P Castelli

Jeffrey P Castelli

Vice President
Enrique Diloné

Enrique Diloné

Vice President
Jay A Barth

Jay A Barth

Chief Medical Officer
Hung Do

Hung Do

Senior Vice President

Amicus Therapeutics Office Locations

Amicus Therapeutics has offices in Cranbury Township, Denham, Munich, Puteaux and in 1 other location
Cranbury Township, US (HQ)
1 Cedar Brook Drive
Puteaux, FR
Tour Défense 2000

Amicus Therapeutics Data and Metrics

Amicus Therapeutics Financial Metrics

Amicus Therapeutics's revenue was reported to be $5 m in FY, 2016
USD

Net income (Q1, 2017)

(55 m)

EBIT (Q1, 2017)

(52 m)

Market capitalization (25-Jul-2017)

2 b

Cash (31-Mar-2017)

44.8 m
Amicus Therapeutics's current market capitalization is $2 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

122.2 m1.2 m5 m

Revenue growth, %

(99%)(100%)

Cost of goods sold

833 k

Gross profit

4.1 m

Gross profit Margin, %

83%

R&D expense

104.8 m

General and administrative expense

71.2 m

Operating expense total

527.8 m69.9 m130.4 m186 m

EBIT

(405.6 m)(68.7 m)(130.4 m)(181.9 m)

EBIT margin, %

(332%)(5613%)(3669%)

Interest expense

46 k1.5 m1.6 m5.4 m

Interest income

174 k223 k929 k1.6 m

Income tax expense

3.5 m1.1 m1.1 m3.7 m

Net Income

(378.5 m)(68.9 m)(132.1 m)(200 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

475 k293 k456 k475 k293 k

Cost of goods sold

344 k775 k

R&D expense

10 m12 m16.1 m17.2 m21 m23.4 m18.3 m32.5 m30.9 m

General and administrative expense

4.8 m5.3 m6.4 m8.3 m15.4 m15.7 m19.3 m17.5 m19.1 m

Operating expense total

14.7 m17.3 m22.5 m25.5 m36.3 m39.1 m37.6 m49.9 m50 m

EBIT

(14.3 m)(16.8 m)(24.1 m)(26.9 m)(38 m)(43 m)(48.5 m)(44.9 m)(52 m)

EBIT margin, %

(3003%)(5739%)(5276%)(5672%)(12985%)

Interest expense

(374 k)(377 k)(372 k)(338 k)(17 k)(945 k)(1.1 m)(1.5 m)(4.3 m)

Interest income

36 k55 k171 k158 k316 k307 k331 k460 k759 k

Income tax expense

453 k253 k(56 k)

Net Income

(30.6 m)(47.7 m)(24.3 m)(51.4 m)(89.2 m)(43.7 m)(94.7 m)(141.4 m)(55 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

43.6 m24.1 m69.5 m187 m

Accounts Receivable

1.3 m

Inventories

5.5 m2.9 m2.6 m3.4 m

Current Assets

88.3 m154.6 m216.6 m340.1 m

Goodwill

11.6 m11.6 m197.8 m197.8 m

Total Assets

127.6 m210 m908.4 m1 b

Accounts Payable

10.2 m16.3 m32.2 m185.5 m

Current Liabilities

10.5 m20.2 m73.6 m111 m

Additional Paid-in Capital

423.6 m568.7 m917.5 m1.1 b

Retained Earnings

(447.4 m)(579.6 m)(779.6 m)

Total Equity

45.8 m122.2 m347.8 m360.2 m

Financial Leverage

2.8 x1.7 x2.6 x2.9 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

41.9 m19.7 m28.8 m249 m19.4 m23.5 m63.7 m33.1 m44.8 m

Accounts Receivable

864 k1.9 m

Inventories

194 k3.3 m3.7 m

Current Assets

79.4 m87.2 m151.3 m365 m240.1 m168.5 m217.7 m221.7 m296.2 m

Goodwill

11.6 m11.6 m11.6 m11.6 m207.6 m197.8 m197.8 m197.8 m197.8 m

Total Assets

118 m125.5 m192.6 m403.9 m986.7 m862.9 m914 m918.2 m993.4 m

Accounts Payable

9.9 m11.3 m15.8 m16.9 m30.6 m22.5 m23.8 m29 m

Current Liabilities

11.2 m13.8 m21 m16.9 m35.9 m64.4 m80.5 m85.6 m109.6 m

Additional Paid-in Capital

444.6 m468.7 m574.8 m826.6 m914.3 m921.2 m990 m1 b1.1 b

Retained Earnings

(409.1 m)(426.2 m)(471.7 m)(498.9 m)(536.7 m)(623.3 m)(674.3 m)(721 m)(834.6 m)

Total Equity

36.3 m43.3 m104 m328.9 m378.8 m311.6 m334.2 m336.6 m310.8 m

Financial Leverage

3.2 x2.9 x1.9 x1.2 x2.6 x2.8 x2.7 x2.7 x3.2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(59.6 m)(68.9 m)(132.1 m)(200 m)

Depreciation and Amortization

1.7 m1.5 m1.8 m3.2 m

Accounts Receivable

(1.4 m)

Inventories

(3.2 m)2.3 m308 k(3.7 m)

Accounts Payable

6.2 m15.5 m7.1 m

Cash From Operating Activities

(45.8 m)(51.7 m)(100.1 m)(150.5 m)

Purchases of PP&E

(695 k)(238 k)(4.8 m)(6 m)

Cash From Investing Activities

(145.3 m)(4.5 m)

Cash From Financing Activities

139.2 m290.9 m272.7 m

Interest Paid

30 k1.2 m605 k3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(30.6 m)(47.7 m)(24.3 m)(51.4 m)(89.2 m)(43.7 m)(94.7 m)(141.4 m)(55 m)

Depreciation and Amortization

808 k1.2 m508 k861 k1.3 m673 k1.4 m2.3 m823 k

Accounts Receivable

(863 k)(512 k)

Inventories

(207 k)(3.5 m)(243 k)

Accounts Payable

(155 k)1.2 m(551 k)459 k14.1 m(9.8 m)(8.2 m)(2.9 m)(1.3 m)

Cash From Operating Activities

(22 m)(37.2 m)(21 m)(43.6 m)(64.6 m)(44.9 m)(77.7 m)(118.5 m)(49.8 m)

Purchases of PP&E

(132 k)(192 k)(753 k)(1.4 m)(2.2 m)(2.9 m)(4.6 m)(5.5 m)(732 k)

Cash From Investing Activities

2.1 m(27.3 m)31.3 m(230.7 m)(39.9 m)(92.4 m)

Cash From Financing Activities

18.2 m40.5 m4.1 m237.2 m290.7 m82.8 m122.4 m(95 k)

Interest Paid

537 k864 k209 k605 k605 k209 k276 k284 k12 k
Y, 2017

Financial Leverage

3.2 x

Amicus Therapeutics Market Value History

Amicus Therapeutics Online and Social Media Presence

Amicus Therapeutics Company Life and Culture

You may also be interested in